HPT: meta-analysis supports F-18 FCH PET/CT for parathyroid localization

  • Kim SJ & al.
  • Horm Cancer
  • 18 Aug 2018

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In a systematic review and meta-analysis, F-18 fluorocholine (FCH) positron emission tomography (PET)/CT had pooled sensitivity of 90% and pooled specificity of 94% for localization of hyperfunctioning parathyroid glands in patients with hyperparathyroidism.

Why this matters

  • This meta-analysis supports the utility of F-18 FCH PET/CT for patients with hyperparathyroidism.

Key results

  • Pooled sensitivity was 90% without heterogeneity (I2, 7.1; P=.375) and pooled specificity was 94% with heterogeneity (I2, 79.8; P=.000).
  • The overall positive likelihood ratio was 5.3 (95% CI, 1.2-24.3) and the overall negative likelihood ratio was 0.15 (95% CI, 0.08-0.29).
  • The pooled diagnostic OR was 38 (95% CI, 8-174).
  • The area under the curve was 0.9492 (standard error, 0.0215) in receiver operating characteristic analysis.

Study design

  • 8 studies were subjected to meta-analysis to determine the diagnostic performance of F-18 FCH PET/CT for localization of hyperfunctioning parathyroid glands.
  • Funding: None disclosed.

Limitations

  • Heterogeneity between studies.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit